Serial No.: 09/974,519

IN THE CLAIMS:

1. (Currently amended) A method of enhancing paracellular permeability at an absorption site in a subject, the method comprising:

- (a) administering an effective amount of a phospholipase C inhibitor to a subject at a time in which enhanced paracellular permeability is desired, wherein the phospholipase C inhibitor is selected from an alkylphosphocholine comprising a straight-chain alkyl of 13 to 20 methylene groups; and
- (b) enhancing paracellular permeability in the subject at the absorption site through the administering of the effective amount of the phospholipase C inhibitor.
- 2. (Canceled)
- 3. (Canceled)
- 4. (Withdrawn) The method of claim 2, wherein the 3-halocoumarin is 3-fluorocoumarin or derivative thereof, 3-chlorocoumarin or derivative thereof, or 3-iodocoumarin or derivative thereof.
- 5. (Withdrawn) The method of claim 2, wherein the N-alkylsuccinimido steroid derivative comprises an alkyl chain of one to ten methylene groups.
- 6. (Original) The method of claim 1, wherein the absorption site comprises intestinal epithelium.
- 7. (Withdrawn) The method of claim 1, wherein the absorption site comprises the blood brain barrier.
- 8. (Original) The method of claim 1, wherein the phospholipase C inhibitor is formulated for oral, buccal, rectal or transdermal administration, or in a form suitable to contact colonic epithelium, or in a form suitable for administration by inhalation or insufflation.
- 9. (Withdrawn) A method of enhancing absorption of a hydrophilic drug in a subject, the method comprising administering an effective amount of a phospholipase C inhibitor to the subject at a time prior to or in conjunction with administering the hydrophilic drug to the subject, whereby enhanced paracellular permeability is produced at an absorption site in the subject; and enhancing absorption of the hydrophilic drug at the

Serial No.: 09/974,519

absorption site in the subject through the administering of the effective amount of the phospholipase C inhibitor.

- 10. (Withdrawn) The method of claim 9, wherein the phospholipase C inhibitor is selected from the group consisting of an alkylphosphocholine, a 3-nitrocoumarin or derivative thereof, a 3-cyanocoumarin or derivative thereof, a 3-halocoumarin or derivative thereof, a 3-acetoxycoumarin or derivative thereof, a coumarin-3-sulfonic acid or derivative thereof, and an N-alkylsuccinimido steroid derivative.
- 11. (Withdrawn) The method of claim 10, wherein the alkylphosphocholine further comprises an alkyl chain of ten to twenty methylene groups.
- 12. (Withdrawn) The method of claim 10, wherein the 3-halocoumarin is 3-fluorocoumarin or derivative thereof, 3-chlorocoumarin or derivative thereof, or 3-iodocoumarin or derivative thereof.
- 13. (Withdrawn) The method of claim 10, wherein the N-alkylsuccinimido steroid derivative comprises an alkyl chain of one to ten methylene groups.
- 14. (Withdrawn) The method of claim 9, wherein the absorption site comprises intestinal epithelium.
- 15. (Withdrawn) The method of claim 9, wherein the absorption site comprises the blood brain barrier.
- 16. (Withdrawn) The method of claim 9, wherein the phospholipase C inhibitor is formulated for oral, buccal, nasal, rectal or transdermal administration, or in a form suitable to contact colonic epithelium, or in a form suitable for administration by inhalation or insufflation.
 - 17. (Withdrawn) A composition comprising:
 - (a) a hydrophilic drug;
 - (b) a phospholipase C inhibiting amount of a phospholipase C inhibitor; and
 - (c) a pharmaceutically acceptable carrier.
- 18. (Withdrawn) The composition of claim 17, wherein the phospholipase C inhibitor is selected from the group consisting of an alkylphosphocholine, a 3-nitrocoumarin or derivative thereof, a 3-cyanocoumarin or derivative thereof, a 3-halocoumarin or derivative thereof, a 3-acetoxycoumarin or derivative thereof, a coumarin-3-sulfonic acid or derivative thereof, and an N-alkylsuccinimido steroid derivative.

Serial No.: 09/974,519

- 19. (Withdrawn) The composition of claim 18, wherein the alkylphosphocholine further comprises an alkyl chain of ten to twenty methylene groups.
- 20. (Withdrawn) The method of claim 18, wherein the 3-halocoumarin is 3-fluorocoumarin or derivative thereof, 3-chlorocoumarin or derivative thereof, or 3-iodocoumarin or derivative thereof.
- 21. (Withdrawn) The method of claim 18, wherein the N-alkylsuccinimido steroid derivative comprises an alkyl chain of one to ten methylene groups.
- 22. (Withdrawn) A method of preparing a composition that facilitates oral availability of a hydrophilic drug to a subject in need thereof, the method comprising:
 - (a) providing a hydrophilic drug;
 - (b) providing a phospholipase C inhibitor; and
 - (c) mixing the hydrophilic drug and a phospholipase C inhibiting amount of the phospholipase C inhibitor with a pharmaceutically acceptable carrier, whereby a composition that facilitates oral availability of the hydrophilic drug is prepared.
- 23. (Withdrawn) The method of claim 22, wherein the phospholipase C inhibitor is selected from the group consisting of an alkylphosphocholine, a 3-nitrocoumarin or derivative thereof, a 3-cyanocoumarin or derivative thereof, a 3-halocoumarin or derivative thereof, a 3-acetoxycoumarin or derivative thereof, a coumarin-3-sulfonic acid or derivative thereof, and an N-alkylsuccinimido steroid derivative.
- 24. (Withdrawn) The method of claim 23, wherein the alkylphosphocholine further comprises an alkyl chain of ten to twenty methylene groups.
- 25. (Withdrawn) The method of claim 23, wherein the 3-halocoumarin is 3-fluorocoumarin or derivative thereof, 3-chlorocoumarin or derivative thereof, or 3-iodocoumarin or derivative thereof.
- 26. (Withdrawn) The method of claim 23, wherein the N-alkylsuccinimido steroid derivative comprises an alkyl chain of one to ten methylene groups.
- 27. (Withdrawn) The method of claim 22, wherein the composition is formulated for oral, buccal, rectal or transdermal administration, or in a form suitable to contact colonic epithelium, or in a form suitable for administration by inhalation or insufflation.